Abzena Expands GMP Potency Testing
Abzena expands GMP cell-based potency assays, enhancing bioassay services at UK and US facilities.
Abzena, a leading CDMO + CRO, has expanded its early and late-phase analytical services to include GMP cell-based potency assays at its Cambridge, UK, and San Diego, CA facilities. This addition enhances its bioassay offerings, enabling faster, more reliable data critical for biopharmaceutical development, including ADC cytotoxicity and GMP product release testing.
The move supports developers in optimizing strategies, meeting regulatory needs, and advancing drug programs efficiently. Abzena remains committed to delivering end-to-end analytical solutions to drive success from discovery through commercialization.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Medicus Pharma soumet à la FDA le protocole de Phase 2b/3 pour Teverelix
Fresenius Kabi reçoit une lettre d’avertissement de la FDA après des défaillances d’enquête sur le traitement aseptique dans l’établissement de Melrose Park
Discussion